This Biotech Flew High, Then Fell Hard When Its Cancer Drug Failed
Nektar Therapeutics was one of biotech’s highfliers, enjoying a generous, multibillion-dollar partnership with cancer powerhouse Bristol-Myers Squibb Co. Then Nektar’s promise crered. After a series of disappointing study results, Bristol and Nektar terminated their partnership, Nektar’s market value is down 96% from its peak in 2018 and the biotech was forced last month to slash …
This Biotech Flew High, Then Fell Hard When Its Cancer Drug Failed Read More »